19:26 , Apr 30, 2019 |  BC Extra  |  Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific  FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor Inc. (NASDAQ:XNCR), which is evaluating the bispecific antibody against CD3 and CD123...
13:50 , Mar 14, 2019 |  BC Extra  |  Financial News

With new data in hand, Axovant raises $40M

Days after revealing the first clinical data from its gene therapy pipeline, Axovant raised $40 million through the sale of 26.7 million shares at $1.50 in a follow-on offering. Axovant Sciences Ltd. (NASDAQ:AXGT) proposed the...
20:28 , Mar 11, 2019 |  BC Extra  |  Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
15:32 , Jun 8, 2018 |  BC Week In Review  |  Company News

Axovant reboots with gene therapy deal

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease. Oxford BioMedica plc...
14:00 , Jun 6, 2018 |  BC Extra  |  Company News

Axovant reboots with gene therapy deal

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease. Oxford BioMedica plc...
07:00 , Mar 9, 2015 |  BioCentury  |  Emerging Company Profile

AAVs for the CNS

Voyager Therapeutics Inc. has a pipeline of adeno-associated viral vector-based gene therapies and is developing novel vectors that are optimized for better distribution in the CNS, among other qualities. Third Rock Ventures launched Voyager about...